Prevalence of fluoroquinolone resistance-associated mutations in Mycoplasma genitalium among clients of two sexual health centres in the Netherlands: a cross-sectional study

Objective This study aimed to determine the prevalence of fluoroquinolone resistance-associated mutations (QRAMs) in Mycoplasma genitalium (MG) among clients of two sexual health centres (SHCs) in the Netherlands. Design A cross-sectional study. Setting and participants Between 2018 and 2019, 669 clients with MG were included from two previous studies: 375 male clients with urethritis from the SHC in Amsterdam; and 294 clients (male and female) from the SHC in Amsterdam and The Hague. Urogenital and anal samples (705 in total) that tested positive for MG by nucleic acid amplification tests were selected. Outcome measures The presence of QRAM was detected by an MG-QRAM PCR targeting four mutations in the parC gene and investigated by sequence analysis of relevant regions of the gyrA and parC genes. Possible risk factors for the presence of QRAM were investigated. Results We found QRAM in 58 of 669 (9%) clients with an MG infection: 36 of 375 (10%) in the study population of men with urethritis and 22 of 294 (7%) in the study population of other clients (including both men and women; p=0.334). Most prevalent mutations in the parC gene were S83I and D87N, occurring in 31 of 60 (52%) and 20 of 60 (33%) samples, respectively. Factors associated with the presence of QRAM were: men who have sex with men (adjusted OR (aOR) 3.4, 95% CI 1.7 to 6.9) and Asian origin (aOR 2.5, 95% CI 1.2 to 5.6). Multidrug resistance (QRAM plus macrolide resistance-associated mutations) was found in 46 of 669 (7%) clients. Conclusions Nine per cent of MG-positive clients from two Dutch SHCs had QRAM. New treatment strategies and antibiotics are needed to treat symptomatic patients with multidrug-resistant MG.

[1]  M. Unemo,et al.  2021 European guideline on the management of Mycoplasma genitalium infections , 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

[2]  S. Bruisten,et al.  Macrolide-Resistant Mycoplasma genitalium Impairs Clinical Improvement of Male Urethritis After Empirical Treatment , 2021, Sexually transmitted diseases.

[3]  S. Bruisten,et al.  High prevalence and resistance rates of Mycoplasma genitalium among patients visiting two sexually transmitted infection clinics in the Netherlands , 2021, International journal of STD & AIDS.

[4]  S. Bruisten,et al.  Evaluating the prevalence and risk factors for macrolide resistance in Mycoplasma genitalium using a newly developed qPCR assay , 2020, PloS one.

[5]  R. Nijhuis,et al.  Prevalence of Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium and Trichomonas vaginalis including relevant resistance-associated mutations in a single center in the Netherlands , 2020, European Journal of Clinical Microbiology & Infectious Diseases.

[6]  B. Vuylsteke,et al.  An alarming high prevalence of resistance-associated mutations to macrolides and fluoroquinolones in Mycoplasma genitalium in Belgium: results from samples collected between 2015 and 2018 , 2020, Sexually Transmitted Infections.

[7]  E. Plummer,et al.  Nonquinolone Options for the Treatment of Mycoplasma genitalium in the Era of Increased Resistance , 2020, Open forum infectious diseases.

[8]  Huiru Chen,et al.  Macrolide and fluoroquinolone associated mutations in Mycoplasma genitalium in a retrospective study of male and female patients seeking care at a STI Clinic in Guangzhou, China, 2016-2018 , 2020, BMC Infectious Diseases.

[9]  R. Kirkcaldy,et al.  Prevalence of Mycoplasma genitalium infection, antimicrobial resistance mutations and symptom resolution following treatment of urethritis. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  T. Pumarola,et al.  Mycoplasma genitalium and antimicrobial resistance in Europe: a comprehensive review , 2020, International journal of STD & AIDS.

[11]  T. Barkham,et al.  Mycoplasma genitalium in Singapore is associated with Chlamydia trachomatis infection and displays high macrolide and Fluoroquinolone resistance rates , 2019, BMC Infectious Diseases.

[12]  S. Garland,et al.  Moxifloxacin and Sitafloxacin Treatment Failure in Mycoplasma genitalium Infection: Association with parC Mutation G248T (S83I) and Concurrent gyrA Mutations. , 2019, The Journal of infectious diseases.

[13]  F. Hagen,et al.  Macrolide-Resistant Mycoplasma genitalium in Southeastern Region of the Netherlands, 2014–2017 , 2019, Emerging infectious diseases.

[14]  N. Low,et al.  De novo mutations drive the spread of macrolide-resistant Mycoplasma genitalium: a mathematical modelling study , 2018, bioRxiv.

[15]  S. Kutsuna,et al.  Mutations in ParC and GyrA of moxifloxacin-resistant and susceptible Mycoplasma genitalium strains , 2018, PloS one.

[16]  Sudhir Kumar,et al.  MEGA X: Molecular Evolutionary Genetics Analysis across Computing Platforms. , 2018, Molecular biology and evolution.

[17]  S. Garland,et al.  Use of Pristinamycin for Macrolide-Resistant Mycoplasma genitalium Infection , 2018, Emerging infectious diseases.

[18]  N. Low,et al.  Prevalence of Mycoplasma genitalium in different population groups: systematic review andmeta-analysis , 2017, Sexually Transmitted Infections.

[19]  P. Horner,et al.  Mycoplasma genitalium Infection in Men , 2017, The Journal of infectious diseases.

[20]  M. Unemo,et al.  Antimicrobial-resistant sexually transmitted infections: gonorrhoea and Mycoplasma genitalium , 2017, Nature Reviews Urology.

[21]  C. Bradshaw,et al.  Management of Mycoplasma genitalium infections – can we hit a moving target? , 2015, BMC Infectious Diseases.

[22]  A. Rowhani-Rahbar,et al.  Mycoplasma genitalium infection and female reproductive tract disease: a meta-analysis. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  S. Garland,et al.  Macrolide resistance and azithromycin failure in a Mycoplasma genitalium-infected cohort and response of azithromycin failures to alternative antibiotic regimens. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  S. Tabrizi,et al.  Azithromycin treatment failure in Mycoplasma genitalium-positive patients with nongonococcal urethritis is associated with induced macrolide resistance. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  T. Deguchi,et al.  Analysis of the gyrA and parC genes of Mycoplasma genitalium detected in first-pass urine of men with non-gonococcal urethritis before and after fluoroquinolone treatment. , 2001, The Journal of antimicrobial chemotherapy.